Tomudex (raltitrexed) / Pfizer, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 49 Diseases   54 Trials   54 Trials   328 News 


12345»
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Tomudex (raltitrexed) / Pfizer, AstraZeneca, Fruzaqla (fruquintinib) / Takeda
    New P2 trial, Metastases:  Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC (clinicaltrials.gov) -  May 23, 2024   
    P2,  N=66, Recruiting, 
  • ||||||||||  Tomudex (raltitrexed) / Pfizer, AstraZeneca
    Journal:  Efficacy and safety of raltitrexed-eluting CalliSpheres (Pubmed Central) -  Feb 16, 2024   
    This study suggests that RTX may be a novel promising candidate drug for prostate cancer therapy. The most common loadable chemotherapeutic drugs in drug-eluting bead transarterial chemoembolization (DEB-TACE) include doxorubicin, epirubicin, etc. CalliSpheres
  • ||||||||||  Tomudex (raltitrexed) / Pfizer, AstraZeneca
    Journal:  Physicochemical Properties and Release Study of Antimetabolite-Incorporated Stearoyl Chitosan. (Pubmed Central) -  Nov 6, 2023   
    The size of SC loaded with antimetabolites ranged from 225 to 369 nm, and their spherical form was verified via a transmission electron microscope. The in vitro release study showed that SC demonstrated controlled drug release, suggesting that SC nanoparticles have significant promise as a delivery strategy for chemotherapy.
  • ||||||||||  methotrexate / Generic mfg.
    Cerebral Spinal Fluid Attenuates the Efficacy of Methotrexate Against Acute Lymphoblastic Leukemia Cells (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_1859;    
    CSF also attenuated the sensitivity of ALL cells to other anti-folates including raltitrexed, trimetrexate, and pralatrexate...Activation of the UPR with thapsigargin, a sarco/endoplasmic reticulum Ca 2+ ATPase (SERCA) inhibitor that triggers ER stress, increased methotrexate resistance in leukemia cells...Moreover, we anticipate that our current work defining the mechanisms driving this resistance may identify novel approaches for maximizing methotrexate efficacy and more completely eradicating leukemia cells in CSF and the CNS. Finally, this work highlights the importance of critically evaluating even long-established standards of care.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Enrollment open, Trial initiation date:  TORCH-R: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer (clinicaltrials.gov) -  Sep 26, 2023   
    P2,  N=93, Recruiting, 
    CB exhibits good loadability and acceptable releasing profile for eluting vinorelbine and raltitrexed, and shows lower Cmax and numerically stable concentration than TAI. Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Aug 2022
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, dubermatinib (TP-0903) / Sumitomo Pharma, Tomudex (raltitrexed) / Pfizer, AstraZeneca
    Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression () -  Aug 14, 2023 - Abstract #IWCLL2023IWCLL_161;    
    When we treated high and low PNP expressing CLL B-cells from untreated patients with drugs known to be active in CLL, interestingly we found high PNP expressing CLL B-cells are sensitive to Bcl2 inhibitor venetoclax and AXL kinase inhibitor TP-0903 versus low PNP expressing CLL B-cells...However treatment of CLL B-cells from untreated patients cultured alone or co-cultured with BMSCs with TYMS inhibitor raltitrexed did not show any killing indicating an alternate role of TYMS in BMSC cultured CLL B-cells...In conclusion, these results indicate that active purine and pyrimidine metabolism in CLL B-cells augmented by the BM environment can support CLL B-cell survival and drug resistance and possible induction of EMT components. Future studies are underway to understand the role and regulation of PNP and TYMS in CLL disease progression and drug resistance for both untreated and treated CLL patients.
  • ||||||||||  Tevimbra (tislelizumab) / BeiGene, Elunate (fruquintinib) / Takeda
    A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for advanced Colorectal Cancer Liver Metastases (CRLM) () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2221;    
    P2
    Eligible pts received fruquintinib (3mg, qd, po, D2-21, Q3W) in combination with tislelizumab (200mg, ivgtt, D2,Q3W) and HAIC (TOMOX: raltitrexed 2mg/m2, D1, oxaliplatin 85mg/m2, D1, Q3W; or TOMIRI: raltitrexed 2mg/m2, D1, irinotecan 120mg/m2, D1, Q3W) for 4-6 cycles, followed by maintenance therapy with fruquintinib and tislelizumab until disease progression, death or unacceptable toxicity...22 and 4 pts had previously received bevacizumab and regorafenib, respectively...Conclusions Fruquintinib combined with tislelizumab and HAIC showed promising efficacy and acceptable safety for CRLM pts who had failed standard therapy in this interim analysis. Updated data will be presented in the future.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Tomudex (raltitrexed) / Pfizer, AstraZeneca, Elunate (fruquintinib) / Takeda
    Clinical, Journal, Metastases:  Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report. (Pubmed Central) -  Mar 15, 2023   
    Fruquintinib, regorafenib, trifluridine/tipiracil (TAS-102), panitumumab and cetuximab combined with single-agent chemotherapy regimens are currently recommended as third-line therapies for patients exhibiting disease progression...The mFOLFOX6 regimen was administered...Liver metastases (intestinal-type adenocarcinoma) were detected in November 2018, and second-line therapy with the FOLFIRI regimen was initiated in January 2019...Third-line therapy with fruquintinib, raltitrexed, and S-1 achieved a PR that permitted surgical resection and enabled a relatively long progression-free survival. The findings suggest that the three agents regimen might be clinically effective as late-line therapy for mCRC.